Sanchez RA, Sanabria H, Santos CL, Ramirez AJ. Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease. World J Diabetes 2015; 6(11): 1186-1197 [PMID: 26380062 DOI: 10.4239/wjd.v6.i11.1186]
Corresponding Author of This Article
Ramiro A Sanchez, MD, PhD, Professor, Head, Arterial Hypertension and Metabolic Unit, University Hospital, Fundación Favaloro, Av. Belgrano 1782, 4.º, Buenos Aires 1093, Argentina. rsanchez@ffavaloro.org
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Sep 10, 2015; 6(11): 1186-1197 Published online Sep 10, 2015. doi: 10.4239/wjd.v6.i11.1186
Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease
Ramiro A Sanchez, Hugo Sanabria, Cecilia de los Santos, Agustin J Ramirez
Ramiro A Sanchez, Agustin J Ramirez, Arterial Hypertension and Metabolic Unit, University Hospital, Fundación Favaloro, Buenos Aires 1093, Argentina
Hugo Sanabria, Diabetes Unit, Instituto Cardiovascular de Buenos Aires, Buenos Aires 1428, Argentina
Cecilia de los Santos, Medical Affairs Department, Boehringer Ingelheim, Munro 1605, Argentina
Author contributions: All the authors equally contributed to this work.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ramiro A Sanchez, MD, PhD, Professor, Head, Arterial Hypertension and Metabolic Unit, University Hospital, Fundación Favaloro, Av. Belgrano 1782, 4.º, Buenos Aires 1093, Argentina. rsanchez@ffavaloro.org
Telephone: +54-11-4371337
Received: August 25, 2014 Peer-review started: August 25, 2014 First decision: December 17, 2014 Revised: August 14, 2015 Accepted: August 30, 2015 Article in press: August 31, 2015 Published online: September 10, 2015 Processing time: 386 Days and 8.3 Hours
Core Tip
Core tip: The dipeptidyl peptidase IV inhibitors prevent the breakdown of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, but also decrease the degradation of several vasoactive peptides. Dipeptidyl peptidase IV inhibitors have shown to have favorable effects in animal models of ischemia/reperfusion and in hypertension. Clinical studies are most under way and final results could give reliable information on cardiovascular protection. Selective inhibitors of renal sodium glucose transport 2 have been also evaluated in the prevention of cardiovascular outcomes in type 2 diabetes. However, data on cardiovascular outcomes and cardiovascular death are limited and long term studies are on-going, therefore it is premature to draw conclusions.
